FIELD: biotechnology.
SUBSTANCE: in particular, the invention includes an antigen-binding protein that specifically binds to EGFR and CD16A, containing antigen-binding sites for EGFR and CD16A.
EFFECT: invention is effective in the treatment of cancer characterized by EGFR-positive or EGFRvIII-positive cells.
11 cl, 34 dwg, 14 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| CRYOPRESERVED CELLS ARE NATURAL KILLERS PRELOADED WITH ANTIBODY CONSTRUCTION | 2019 |
|
RU2819927C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF USE THEREOF | 2014 |
|
RU2815683C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
